![calcusyn v2 calcusyn v2](https://openi.nlm.nih.gov/imgs/512/52/4770749/PMC4770749_oncotarget-06-38952-g001.png)
![calcusyn v2 calcusyn v2](https://lasopaebay273.weebly.com/uploads/1/2/6/3/126334599/454522738.jpg)
Ĭahill KE, Morshed RA, Yamini B (2016) Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy. (00)80045-3īurkhard C, Di Patre PL, Schüler D et al (2003) A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. īrassesco MS, Roberto GM, Morales AG, Oliveira JC, Delsin LEA, Pezuk JA, Valera ET, Carlotti CG, Rego EM, de Oliveira HF, Scrideli CA, Umezawa K, Tone LG (2013) Inhibition of NF- κ B by dehydroxymethylepoxyquinomicin suppresses invasion and synergistically potentiates temozolomide and γ-radiation cytotoxicity in glioblastoma cells.
![calcusyn v2 calcusyn v2](https://ars.els-cdn.com/content/image/1-s2.0-S2666379121000896-gr3.jpg)
īobola MS, Silber JR, Ellenbogen RG et al (2005) O6-methylguanine-DNA methyltransferase, O6- benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Moreover, its use might assist adjuvant chemotherapy and reduce irradiation doses to avoid toxicity to the surrounding tissues.īikowska-Opalach B, Szlufik S, Grajkowska W, Jozwiak J (2014) Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers. This drug presents a potential application in clinical practice for the treatment of recurrent or inoperable PA. Moreover, DHMEQ treatment significantly reduced cell growth and motility, while sensitized cells to ionizing radiation and TMZ, as previously seen in high-grade gliomas. Our results showed that all the members of the NF-kB family are upregulated in PA datasets compared to normal brain tissues. Sensitization to radiation therapy and temozolomide (TMZ) was also assayed. Besides, in vitro assays were performed to evaluate proliferation, migration, cell death, on the PA cell line Res286 comparing to human primary astrocytes. In the present study, we used publicly available data for the in silico analysis of NF-κB subunits ( RELA, RELB, REL, NF-κB1, and NF-κB2) expression in PA samples. Besides BRAF, CDKN2A, or IDH mutations, the hyperactivation of the nuclear factor NF-κB contributes to tumor growth and survival. Even though PA is benign and treatment only involves surgery, recurrent or unresectable tumors require chemo- and radiotherapy.